SI-BONE To Report Third Quarter 2022 Financial Results on November 7, 2022

Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN) announced it will release its third-quarter 2022 financial results on November 7, 2022, post-market close. A conference call will follow at 1:30 PM PT / 4:30 PM ET, allowing investors to engage in a discussion regarding the results. SI-BONE is recognized for its iFuse Implant System aimed at treating sacropelvic disorders, with over 70,000 procedures performed by more than 2,800 surgeons. The company has established a strong reimbursement advantage, supporting its market leadership in minimally invasive surgical solutions.

Positive

• Established strong reimbursement advantage for iFuse Implant System, expanding coverage.
• More than 70,000 SI joint fusion procedures performed, demonstrating market demand.
• Over 2,800 surgeons trained in utilizing the iFuse Implant System, indicating broad acceptance.

Negative

• None.

SANTA CLARA, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2022 after market close on Monday, November 7, 2022. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/cax4w498. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since 2009, when SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, more than 2,800 surgeons have performed a combined total of more than 70,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two randomized controlled trials and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish near-universal coverage of minimally invasive SI joint fusion, including many payors that cover the procedure exclusively when performed with the iFuse Implant System. Supported by this proprietary reimbursement advantage, SI-BONE has actively leveraged its market leadership position in recent years to further clinical research, and evolve and commercialize novel surgical treatment solutions for SI-Joint pain, sacropelvic and pelvic fixation, and pelvic trauma.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2022 SI-BONE, Inc. All Rights Reserved.

Investor Contact:

Marissa Bych
investors@SI-BONE.com

FAQ

When will SI-BONE release its financial results for Q3 2022?

SI-BONE will release its financial results on November 7, 2022, after market close.

What time is the conference call for SI-BONE's Q3 2022 results?

The conference call will begin at 1:30 PM Pacific Time / 4:30 PM Eastern Time.

How many SI joint fusion procedures have been performed using the iFuse Implant System?

More than 70,000 SI joint fusion procedures have been performed with the iFuse Implant System.

How many surgeons use the iFuse Implant System?

Over 2,800 surgeons have adopted the iFuse Implant System for procedural use.